vs

Side-by-side financial comparison of Healthcare Realty Trust Inc (HR) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Healthcare Realty Trust Inc is the larger business by last-quarter revenue ($279.0M vs $151.7M, roughly 1.8× Tarsus Pharmaceuticals, Inc.). Healthcare Realty Trust Inc runs the higher net margin — -0.0% vs -5.5%, a 5.5% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 5.9%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -6.1%).

Duke Realty was a real estate investment trust (REIT) based in Indianapolis, Indiana, that invested in industrial properties. As of December 31, 2021, it owned or jointly controlled 548 primarily industrial properties containing 162.7 million rentable square feet. In October 2022, it was acquired by Prologis.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

HR vs TARS — Head-to-Head

Bigger by revenue
HR
HR
1.8× larger
HR
$279.0M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+122.5% gap
TARS
128.4%
5.9%
HR
Higher net margin
HR
HR
5.5% more per $
HR
-0.0%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-6.1%
HR

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
HR
HR
TARS
TARS
Revenue
$279.0M
$151.7M
Net Profit
$-56.0K
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
-0.0%
-5.5%
Revenue YoY
5.9%
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$0.00
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HR
HR
TARS
TARS
Q1 26
$279.0M
Q4 25
$286.3M
$151.7M
Q3 25
$297.8M
$118.7M
Q2 25
$297.5M
$102.7M
Q1 25
$299.0M
$78.3M
Q4 24
$309.8M
$66.4M
Q3 24
$315.4M
$48.1M
Q2 24
$316.3M
$40.8M
Net Profit
HR
HR
TARS
TARS
Q1 26
$-56.0K
Q4 25
$14.6M
$-8.4M
Q3 25
$-57.7M
$-12.6M
Q2 25
$-157.9M
$-20.3M
Q1 25
$-44.9M
$-25.1M
Q4 24
$-108.2M
$-23.1M
Q3 24
$-93.0M
$-23.4M
Q2 24
$-143.8M
$-33.3M
Operating Margin
HR
HR
TARS
TARS
Q1 26
Q4 25
-5.3%
Q3 25
-12.2%
Q2 25
-21.6%
Q1 25
-33.5%
Q4 24
-36.8%
Q3 24
-52.3%
Q2 24
-81.6%
Net Margin
HR
HR
TARS
TARS
Q1 26
-0.0%
Q4 25
183.4%
-5.5%
Q3 25
-19.4%
-10.6%
Q2 25
-53.1%
-19.8%
Q1 25
-15.0%
-32.1%
Q4 24
-1924.1%
-34.8%
Q3 24
-29.5%
-48.7%
Q2 24
-45.5%
-81.6%
EPS (diluted)
HR
HR
TARS
TARS
Q1 26
$0.00
Q4 25
$0.04
$-0.17
Q3 25
$-0.17
$-0.30
Q2 25
$-0.45
$-0.48
Q1 25
$-0.13
$-0.64
Q4 24
$-0.34
$-0.57
Q3 24
$-0.26
$-0.61
Q2 24
$-0.39
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HR
HR
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$26.2M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$4.4B
$343.4M
Total Assets
$9.1B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HR
HR
TARS
TARS
Q1 26
$26.2M
Q4 25
$26.2M
$417.3M
Q3 25
$43.3M
$401.8M
Q2 25
$25.5M
$381.1M
Q1 25
$25.7M
$407.9M
Q4 24
$68.9M
$291.4M
Q3 24
$22.8M
$317.0M
Q2 24
$41.8M
$323.6M
Total Debt
HR
HR
TARS
TARS
Q1 26
Q4 25
$3.9B
$72.4M
Q3 25
$4.5B
$72.3M
Q2 25
$4.7B
$72.1M
Q1 25
$4.7B
$72.0M
Q4 24
$4.7B
$71.8M
Q3 24
$5.0B
$71.7M
Q2 24
$5.1B
$71.6M
Stockholders' Equity
HR
HR
TARS
TARS
Q1 26
$4.4B
Q4 25
$4.6B
$343.4M
Q3 25
$4.7B
$335.1M
Q2 25
$4.8B
$332.6M
Q1 25
$5.1B
$342.5M
Q4 24
$5.2B
$224.5M
Q3 24
$5.5B
$237.5M
Q2 24
$5.9B
$252.2M
Total Assets
HR
HR
TARS
TARS
Q1 26
$9.1B
Q4 25
$9.2B
$562.2M
Q3 25
$9.9B
$534.6M
Q2 25
$10.2B
$495.0M
Q1 25
$10.5B
$500.8M
Q4 24
$10.7B
$377.0M
Q3 24
$11.2B
$376.3M
Q2 24
$11.8B
$376.8M
Debt / Equity
HR
HR
TARS
TARS
Q1 26
Q4 25
0.85×
0.21×
Q3 25
0.96×
0.22×
Q2 25
0.97×
0.22×
Q1 25
0.93×
0.21×
Q4 24
0.89×
0.32×
Q3 24
0.90×
0.30×
Q2 24
0.87×
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HR
HR
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
9.7%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HR
HR
TARS
TARS
Q1 26
Q4 25
$457.1M
$19.3M
Q3 25
$113.8M
$18.3M
Q2 25
$163.2M
$-29.4M
Q1 25
$47.8M
$-20.7M
Q4 24
$501.6M
$-22.2M
Q3 24
$119.3M
$-8.7M
Q2 24
$168.2M
$-14.4M
Free Cash Flow
HR
HR
TARS
TARS
Q1 26
Q4 25
$13.0M
Q3 25
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
FCF Margin
HR
HR
TARS
TARS
Q1 26
Q4 25
8.6%
Q3 25
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Capex Intensity
HR
HR
TARS
TARS
Q1 26
9.7%
Q4 25
4.2%
Q3 25
1.6%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Cash Conversion
HR
HR
TARS
TARS
Q1 26
Q4 25
31.33×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HR
HR

Rental income$267.6M96%
Other$11.4M4%

TARS
TARS

Segment breakdown not available.

Related Comparisons